Your patients rely on you for clarity and confidence at every turn. With solutions that support planning and initial evaluation through post-treatment assessments, our fertility-focused testing portfolio helps you feel confident that you and your patients can access the right tests that deliver the right insights.
Explore a study showing consistent results between delayed, mail-in semen analyses and in-clinic analyses.
Genetic carrier screening is a key step in assessing aspiring parents’ reproductive risks. The QHerit® product portfolio is designed to give you clear insights into a couple’s genetic makeup—so you can guide informed, confident decisions about family planning. Our QHerit panels are ever evolving; currently we offer 5 screening panel options for up to 611 diseases to help you to select a medically appropriate panel based on your patient’s needs. Our panels are designed with American College of Obstetricians and Gynecologists (ACOG) guidelines and American College of Medical Genetics and Genomics (ACMG) Practice Resources in mind. Individual component tests of the QHerit panels are available to be ordered separately.
As part of our specialized fertility solutions, our reproductive donor testing delivers the speed, convenience, and accuracy you need, without the complexity. With an extensive menu for both male and female donors and a simplified ordering process through your EMR or Quanum Lab Services Manager, we aim to make the process easier. Plus, our dedicated customer service team provides white-glove support to ensure your donor testing needs are met with precision and care at every step.
We know that no two fertility journeys are the same. As you make decisions based on individual patient needs, we're here to help support you in building a diagnostic path designed for one patient at a time.
Initial workup, pre-treatment, and treatment planning panels mirror the fertility journey end-to-end (eg, AMH, FSH/LH, donor screening, carrier screening, etc)
Flexible test groupings help you personalize care as patients move through their unique journey, with testing that adapts to evolving clinical needs and fertility planning
High-volume and frequently ordered tests help you meet real-world patient demands at scale
With the right mix of diagnostic solutions and support services, we are here to make the fertility journey smoother for both you and your patients. Our goal is to remove complexity—so you can stay focused on delivering care, not managing paperwork, chasing results, or coordinating logistics. From streamlined testing to reliable service, we are your partner in creating a more seamless experience at every step.
Interested in how we can support you? Tailored solutions, expert insights, and a clear path forward—available only when you connect with our team.
Fill out the form below and we'll be in touch.
*QHerit® 22, QHerit 112, QHerit 198, QHerit 445, and QHerit 611 are carrier screening tests, and they screen for variations in genes linked to certain health disorders that can be passed from parents to children. QHerit 22 screens for 24 genes, QHerit 112 screens for 113 genes, QHerit 198 screens for 199 genes, QHerit 445 screens for 446 genes, and QHerit 611 screens for 612 genes. For a full list of genes that each panel in the QHerit family screens, visit QHerit.com. If the results from any panel in the QHerit family suggest that a patient may be a carrier of a gene variation that can cause a health disorder in her offspring, it is recommended that her reproductive partner be offered genetic screening, and that genetic counseling be provided. Pregnancy management decisions should not be based on the results of these screening tests alone. As with any test, there may be false positives or false negatives. The positive predictive value of the screening test varies by genetic variation and may be lower for rare conditions. Each panel in the QHerit family is a laboratory-developed test that has been developed and validated pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA) and, as such, it has not been reviewed by FDA.
QHerit panels are screening tests. QHerit does not diagnose a disease or disorder.
Panel components for males do not include specified X-linked diseases.
†Reproductive donor testing is conducted in our FDA-registered transplant laboratory in Chantilly, VA.
‡ReproSource is a national leader in specialty fertility diagnostic services. While ReproSource is a Quest Diagnostics affiliate, ReproSource and Quest are separate companies. As such, health plan access, test ordering, and billing processes may differ from those of Quest Diagnostics. Please note that ReproSource is not a Medicare/Medicaid provider. For more information, please contact ReproSource at 1.800.667.8893 or visit ReproSource.com/Contact-Us.
§This is directional data. It is based on 2020 Health Leaders membership data of private third-party payers at the Managed Care Organization (MCO) level, as well as Quest internal data. Information is believed to be accurate as of January 1, 2020; however, it is subject to change.
Your Privacy Choices
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.
